PI3K/AKT/mTOR has been frequently mutated in other cancers and rapamycin has been often used clinically.42,43 If targeting endogenous MYC and mTOR pathway can counteract the limitation of rapamycin, the combination treatment of rapalogs with BETi will be beneficial not only in NETs but also in other cancers. This evidence concerns the gene MTOR and cancer.